ELVN vs. KRYS, RYTM, CYTK, PTCT, ZLAB, ACAD, MRUS, ACLX, SWTX, and RNA
Should you be buying Enliven Therapeutics stock or one of its competitors? The main competitors of Enliven Therapeutics include Krystal Biotech (KRYS), Rhythm Pharmaceuticals (RYTM), Cytokinetics (CYTK), PTC Therapeutics (PTCT), Zai Lab (ZLAB), ACADIA Pharmaceuticals (ACAD), Merus (MRUS), Arcellx (ACLX), SpringWorks Therapeutics (SWTX), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry.
Enliven Therapeutics vs. Its Competitors
Enliven Therapeutics (NASDAQ:ELVN) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.
Enliven Therapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.
Krystal Biotech has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
Krystal Biotech has a net margin of 37.17% compared to Enliven Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 14.64% beat Enliven Therapeutics' return on equity.
95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 25.9% of Enliven Therapeutics shares are owned by company insiders. Comparatively, 13.7% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Krystal Biotech had 2 more articles in the media than Enliven Therapeutics. MarketBeat recorded 13 mentions for Krystal Biotech and 11 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.68 beat Krystal Biotech's score of -0.02 indicating that Enliven Therapeutics is being referred to more favorably in the media.
Enliven Therapeutics presently has a consensus price target of $41.20, indicating a potential upside of 106.72%. Krystal Biotech has a consensus price target of $211.13, indicating a potential upside of 47.29%. Given Enliven Therapeutics' higher possible upside, equities analysts clearly believe Enliven Therapeutics is more favorable than Krystal Biotech.
Summary
Krystal Biotech beats Enliven Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Enliven Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ELVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enliven Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ELVN) was last updated on 7/9/2025 by MarketBeat.com Staff
Free ELVN Stock Alerts